康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 10-15 16:23:07 EDT

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"10-15 16:23:07 EDT","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792108800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO/wiki","defaultTab":"wiki","newsList":[{"id":"2675094370","title":"南方港股医药三季报解码，减权益、加CXO，资金在押注什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675094370","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675094370?lang=zh_cn&edition=full","pubTime":"2026-10-15 13:05","pubTimestamp":1792040700,"startTime":"0","endTime":"0","summary":"一、净值与份额同步增长，权益占比下降10月13日，南方港股医药行业混合基金率先披露2026年公募基金行业首份三季报，基金经理对医药行业的最新观点随之出炉。得益于三季度港股医药板块(如恒 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261015/c680723687.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261015/c680723687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["CXO","159718","WX","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675381393","title":"港股CXO概念股盘初下挫，金斯瑞生物科技跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675381393","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675381393?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:34","pubTimestamp":1791855288,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","CXO","KCAI","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674892318","title":"【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674892318?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","BK1521","09926","01801","CXO","LU1008478684.HKD","LU0823426308.USD","LU0320764599.SGD","WX","LU0348827113.USD","LU2097828714.EUR","01177","LNGR","MEDX","IE00B5MMRT66.SGD","LU1242518931.SGD","LU1960683339.HKD","06821","LU0572944931.SGD","IE00BZ08YR35.GBP","IBBQ","BK1500","LU2125910500.SGD","02359","159992","LU0307460666.USD","BK1191","IE0008369823.USD","LU2399975544.HKD","01093","LU0348767384.USD","LU1688375341.USD","KCE","02269","00013","LU0561508036.HKD","LU1831875114.USD","LU0067412154.USD","LU2097828557.USD","LU0708995153.HKD","KURE","LU2488822045.USD","LU0149534421.HKD","06160","06978","SG9999002463.SGD","LU0029874905.USD","LU0314109678.HKD","02268","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2673035134","title":"小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673035134?lang=zh_cn&edition=full","pubTime":"2026-10-06 11:32","pubTimestamp":1791257520,"startTime":"0","endTime":"0","summary":"另外，该行预期本轮加息周期将于12月再加息一次后结束，而非延续至明年的长期紧缩，因此对利率上升影响中国医疗健康估值并不太担心，并继续看好生物科技及CXO子板块。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03696","02268","159837","CXO","MEDX","LNGR","LU0345769631.USD","TFNS","VHT","LU1670627923.USD","VFH","LU0345769128.USD","IXJ","LU0572944931.SGD","FTXO","02269","IYF","JPO","LU0976567544.SGD","SYNB","KURE","WX","XBI","IE0034235295.USD","LABU","IE00BKDWB100.SGD","06990","159760","01548","PEX","UYG","IBBJ","TRUF","FNCL","GDOC","XLV","LU2168564065.EUR","02359","LU0708995153.HKD","HBImain","XLF","IEIH","IYG","LU1974910355.USD","JPMO","KBWB","AGNG","EQRR","IXG","XLBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672758061","title":"创新药出海之后，CXO能否接住订单复苏？","url":"https://stock-news.laohu8.com/highlight/detail?id=2672758061","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672758061?lang=zh_cn&edition=full","pubTime":"2026-10-01 16:18","pubTimestamp":1790842680,"startTime":"0","endTime":"0","summary":"9月医药板块的重估，起点是创新药出海交易的密集落地，真正决定行情能否继续的，却是一个更具体的问题：BD交易能否转化为CXO产业链的订单、收入和利润？公开资料显示，国家药监局9月14日披 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261001/c680429674.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261001/c680429674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","06978","IBBQ","LNGR","CXO","WX","MEDX","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671271309","title":"科创板收评：权重股拖累科创50指数下行 创新药械、CXO板块逆势爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2671271309","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671271309?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:04","pubTimestamp":1790751854,"startTime":"0","endTime":"0","summary":"今日，科创50指数收跌2.58%。盘面上，寒武纪、中芯国际、海光信息、澜起科技等权重股普遍下挫。分行业来看，创新药械、CXO板块逆势爆发，康希诺、泰诺麦博20cm涨停，南模生物涨超19%，近岸蛋白涨超13%，洁特生物涨超12%。半导体板块情绪低迷，芯原股份跌超11%，气派科技、杰华特跌超7%，华峰测控跌超6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202609303887676434.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202609303887676434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["CXO","KSTR","399265","159371","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671725228","title":"盈利修复叠加出海提速，创新药与CXO投资机遇受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2671725228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671725228?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:14","pubTimestamp":1790723656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","CXO","IBBQ","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670224407","title":"CXO概念活跃 华神科技涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2670224407","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670224407?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:32","pubTimestamp":1790559162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488353","title":"港股医药实力抗跌！CXO再扛旗，核心ETF（159137）逆市收红，金斯瑞创5年新高！两个问题引发关注……","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488353","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669488353?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:17","pubTimestamp":1790162220,"startTime":"0","endTime":"0","summary":"AI制药产业链上游CXO全天强势，百奥赛图-B领涨近5%，金斯瑞生物科技再涨3.21%创5年新高！港股通医疗ETF华宝标的指数AI制药含量近70%，盘中冲高1.4%，收涨0.1%。图：港股通创新药ETF华宝近6月走势近期港股创新药链相对强势，回顾行情结构，两个问题引发关注：其一，AI制药热度走高，为什么CXO涨势更优。港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，7成仓位押注创新药研发龙头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-23/doc-inisvivx8562452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","159718","159137","CXO","BK4585","KURE","FDN","WX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU0516422440.USD","09939","01873","603127","03759","BK1610","LU0307460666.USD","LU0359201612.USD","LU0540923850.HKD","LU0051755006.USD","BK1583","LU0359202008.SGD","LU1794554557.SGD","LU0456846285.SGD","LU0043850808.USD","LU0561508036.HKD","KURE","02269","LU0029874905.USD","LU0348766576.USD","LU1880383366.USD","SG9999002463.SGD","LU0348825331.USD","LU3063872942.SGD","BK1589","CXO","06127","03347","HK0000306701.USD","LU0516422366.SGD","BK1515","LU0181495838.USD","WX","02359","BK1141","BK1161","HK0000320223.HKD","LU0029874061.USD","LU1242518857.USD","LU0052750758.USD","LU0320764599.SGD","159938","LU0516422952.EUR","LU2125910500.SGD","LU2242644610.SGD","LU0516423091.SGD","01548","LU0588546209.SGD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874905.USD","BK1610","LU3063872942.SGD","LU1880383366.USD","LU0181495838.USD","LU0588546209.SGD","LU1251922891.USD","IE00B0JY6N72.USD","WX","LU0348827113.USD","01873","LU0469268626.HKD","LU1242518931.SGD","LU0516423174.USD","LU0320764243.SGD","LU0456846285.SGD","CXO","LU0634319403.HKD","06160","LU0228659784.USD","LU1719994722.HKD","LU0039217434.USD","03347","LU0348825331.USD","LU0052750758.USD","SG9999002562.SGD","603127","LU0029874061.USD","LU0051755006.USD","02359","06127","LU0320764599.SGD","01548","LU2242644610.SGD","KURE","LU0128522744.USD","BK1588","02269","LU2039709279.SGD","BK1521","LU0359202008.SGD","LU0828237510.HKD","LU1242518857.USD","06821","BK1161","BK0216","LU0561508036.HKD","LU0856984785.SGD","LU1688375341.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930626","title":"港股异动 | CRO概念股涨幅居前 AIDD利好催化密集 CXO板块景气度明确上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668930626?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:08","pubTimestamp":1789610899,"startTime":"0","endTime":"0","summary":"消息面上，近期，AIDD利好催化密集。招商证券近期研报指出，CXO板块景气度明确上行。今年上半年国内CXO板块营收、归母净利润同比分别增长24.5%、52.7%，利润增速接近上一轮周期高点；在手订单与新签订单全面回暖，龙头上调全年指引。此外，AI制药有望重塑医药研发业态，提升药物研发效率，板块亦将受益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK1576","CXO","VXUS","BK1161","02315","BK1191","HK0000320223.HKD","WX","HK0000306701.USD","BK4585","BK1583","HK0000306685.HKD","06821","BK1141","KCAI","BK4588","01548","01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667218626","title":"生物制品及CXO行业集体与投资者互动 企业“出海”进阶 从产品输出迈向能力输出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667218626","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667218626?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:16","pubTimestamp":1789488960,"startTime":"0","endTime":"0","summary":"9月15日，科创板细分行业集体业绩说明会之生物制品及CXO（医药外包服务）行业集体业绩说明会召开，多家上市公司高管出席。从投资者互动的情况中可知，对于生物制品及CXO行业上市公司，关注的主要事项集中在“出海”、研发等方面。在互动过程中，相关公司高管进行了详细解答。在相关上市公司的半年报和互动过程中，“加大海外市场拓展力度”等信息被频繁提及。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875135164.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875135164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667165628","title":"中信建投：内外需改善逐步传导订单与业绩 CXO有望进入新一轮增长阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667165628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667165628?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:50","pubTimestamp":1789372227,"startTime":"0","endTime":"0","summary":"随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WX","BK0276","CXO","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"东北证券：创新药BD和商业化持续兑现 CXO超预期，传统板块筑底拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666513175?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000686","CXO","06978","IBBQ","BK0183","BK0188","BK1574","LNGR","BK0276","MEDX","WX","BK1161","BK0028","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934734","title":"分拆上市成利好？金斯瑞大反攻，飙升逾12%！华宝基金港股通医疗ETF（159137）标的指数涨近2%，CXO全线提振","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934734","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665934734?lang=zh_cn&edition=full","pubTime":"2026-09-08 14:06","pubTimestamp":1788847560,"startTime":"0","endTime":"0","summary":"CXO概念集体走强，金斯瑞生物科技飙升逾12%，百奥赛图-B涨超9%，泰格医药、凯莱英涨超7%，药明合联涨超4%。港股通医疗ETF华宝标的指数CXO含量超50%，午后涨近2%！全链布局创新药，关注两大T+0交易利器：港股通医疗ETF华宝：被动跟踪港股通医疗主题指数，重仓创新药产业链，50%CXO+20%创新药，其中药明系占比超38%。港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-08/doc-inirayqy9498188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159137","159828","WX","FLHK","ACTV","SPIT","CSD","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319763","title":"昊海生科：关于参加科创板2026年半年度生物制品及CXO行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319763","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319763?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，昊海生科发布公告称，公司计划于2026年9月15日15：00-17：00参加由上海证券交易所主办的科创板2026年半年度生物制品及CXO行业集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","WX","CXO","BK0239","KSTR","688366"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"创新药三大指数上涨、ETF吸金，CXO及科研服务呈高景气度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665369630?lang=zh_cn&edition=full","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK4588","IBBQ","06978","LNGR","BK1574","MEDX","FDN","WX","BK4550","CXO","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855519","title":"医疗器械迎业绩拐点？512170成功收红！AI4S带火港股CXO，金斯瑞涨超7%！港股通医疗ETF华宝逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855519","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664855519?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:12","pubTimestamp":1788261120,"startTime":"0","endTime":"0","summary":"9月1日，A股港股医疗板块逆市表现，医疗ETF华宝、港股通医疗ETF华宝等相关品种热度再升温。医疗器械方面，英科医疗上半年营收、净利双增，迈瑞医疗利润降幅显著收窄至5.4%，联影医疗营收同比增长17%。中信建投研报指出，医疗器械行业迎来业绩修复拐点，2026Q2归母净利润实现四年首正增长，板块整体企稳回升。聚焦医疗器械+医疗服务，CXO含量超30%，兼顾脑机接口、AI医疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-01/doc-iniqipis4811448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FLHK","BK1574","VXUS","512170","GDOC","159883","WX","PTH","AGNG","BK4588","KCAI","LNGR","IEIH","HART","BK4585","MEDX","09996","MDEV","CXO","BK1583","LGHT","RSPH","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664896628","title":"招商证券： 需求释放 CXO板块景气度明确上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896628","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664896628?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:09","pubTimestamp":1788221376,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","600999","BK0188","BK0012","BK0276","BK1564","BK1147","CXO","BK0010","BK0183","06099","WX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0115},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.1621},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}